Category Archives: In the Pipeline

“The Best Drug Companies Of The Past 15 Years?”

Matt Herper in Forbes’ “the Medicine Show” posts a point of view by Bernard Munos on what firms have done best in terms of approved drugs since 1995.  The link is here (, as are my comments on this provocative topic.  … Continue reading

Posted in Core Learnings, Financial, In the Pipeline | 1 Comment



The R&D Returns “Ceiling”

BioPharma firms vary greatly in their ability to bring novel therapies to market – what causes some to underperform? Continue reading

Posted in General Interest, In the Pipeline | Tagged , , , | 3 Comments